Price movement over the last 24 hours
Alcon AG vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Vanguard Total Stock Market Index Fund ETF trades at $367.75. The key difference: Alcon AG pays a 0.54% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | VTI | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | — |
52-Week High | $92.22 | $374.36 |
52-Week Low | $62.02 | $305.58 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VTI trades at $371.67, up 0.79% today, with a bullish technical outlook supported by moving averages. The ETF offers broad U.S. equity exposure across 3,400+ stocks with a minimal 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and comparisons with competing total market ETFs, reinforcing its popularity for long-term wealth building.
VTI presents a low-cost core holding for diversified U.S. stock exposure, though its neutral oscillators and elevated short-term RSI suggest near-term consolidation risks. Market volatility and economic shifts remain key headwinds, but analyst sentiment favors its long-term growth potential amid accelerating small-cap earnings.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →